Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 783 across all filing types
Latest filing 2021-08-12 Earnings Release
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
Earnings Release 2021
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions "Item 2.02 Results of Operations and Financial Condition" and states that the company issued a press release announcing financial results for the quarter ended June 30, 2021. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length is 3186 characters, which is relatively short and consistent with a report announcing results rather than the full earnings report. According to the rules, initial announcements of quarterly financial results (key highlights only) are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2021-08-12 English
FORM 10-Q
Interim / Quarterly Report Q2 2021
2021-08-11 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 13, 2021. It announces a press release regarding regulatory approval for a clinical trial protocol amendment. The document is short (3863 characters) and primarily serves as a disclosure of a press release rather than containing detailed financial data or comprehensive report content. It includes a statement that the press release is attached as an exhibit and that the information is being furnished, not filed, indicating it is an announcement rather than a full report. There are no financial statements or substantive financial analysis present. Therefore, this document fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories.
2021-07-13 English
FORM 4
Director's Dealing
2021-07-12 English
FORM 4
Director's Dealing
2021-07-06 English
FORM 424B5
Capital/Financing Update Classification · 95% confidence The document is a Form 424B5 prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933. It details a securities offering involving the issuance and sale of common stock to Lincoln Park Capital Fund, LLC, including terms of the purchase agreement, share amounts, pricing, and use of proceeds. The document includes detailed offering terms, risk factors, and legal disclaimers typical of a capital raising filing. It is not a financial report, earnings release, or management discussion, but rather a capital/financing update related to a stock offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support a high confidence in this classification.
2021-06-25 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.